EGFR and breast cancer: CDK12 has been implicated as a pro-tumorigenic factor in breast cancer, primarily due to its co-amplification with the HER2 oncogene and its synergistic interaction with oncogenic pathways such as WNT and IRS1-ErbB-PI3K signaling [17, 18].